Filtered By:
Specialty: Cardiology
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 800 results found since Jan 2013.
Phosphorylation of USP20 on Ser334 by IRAK-1 Promotes IL-1 β-evoked Signaling in Vascular Smooth Muscle Cells and Vascular Inflammation
J Biol Chem. 2023 Jun 11:104911. doi: 10.1016/j.jbc.2023.104911. Online ahead of print.ABSTRACTReversible lysine-63 (K63) polyubiquitination regulates pro-inflammatory signaling in vascular smooth muscle cells (SMCs), and plays an integral role in atherosclerosis. Ubiquitin-specific peptidase 20 (USP20) reduces NFκB activation triggered by pro-inflammatory stimuli, and USP20 activity attenuates atherosclerosis in mice. The association of USP20 with its substrates triggers deubiquitinase activity; this association is regulated by phosphorylation of USP20 on Ser334 (mouse) or Ser333 (human). USP20 Ser333 phosphorylation was...
Source: Atherosclerosis - June 13, 2023 Category: Cardiology Authors: Lisheng Zhang Jiao-Hui Wu Pierre-Yves Jean-Charles Pavitra Murali Wenli Zhang Aeva Jazic Suneet Kaur Igor Nepliouev Jonathan A Stiber Kamie Snow Neil J Freedman Sudha K Shenoy Source Type: research
Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations
This article describes the relevance of new data for low density lipoprotein-effective therapy: inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), adenosine triphosphate (ATP) citrate lyase with bempedoic acid, and ANGPTL3 with special consideration of primary lipid metabolism disorders, which are insufficiently taken into account, or not taken into account at all, in current guidelines. This is due to their apparently low prevalence rate and thus the lack of large outcome studies. The authors also discuss the consequences of increased lipoprotein (a), which cannot be sufficiently reduced until the ongoin...
Source: Atherosclerosis - June 6, 2023 Category: Cardiology Authors: G Klose I Gouni-Berthold W M ärz Source Type: research
GP73 enhances the ox-LDL-induced inflammatory response in THP-1 derived macrophages via affecting NLRP3 inflammasome signaling
CONCLUSIONS: We demonstrated that GP73 promoted the ox-LDL-induced inflammation in macrophages by affecting the NF-κB/NLRP3 inflammasome signaling, and may play a role in atherosclerosis.PMID:37271284 | DOI:10.1016/j.ijcard.2023.05.059
Source: Atherosclerosis - June 4, 2023 Category: Cardiology Authors: Yi-Fen Lin Miao-Hong Li Ri-Hua Huang Shao-Zhao Zhang Xing-Feng Xu Hui-Min Zhou Meng-Hui Liu Xin-Xue Liao Li-Zhen Liao Yue Guo Xiao-Dong Zhuang Source Type: research
TM6SF2 reduces lipid accumulation in vascular smooth muscle cells by inhibiting LOX-1 and CD36 expression
Exp Cell Res. 2023 Jun 2:113666. doi: 10.1016/j.yexcr.2023.113666. Online ahead of print.ABSTRACTTM6SF2, predominantly expressed in the liver and intestine, is closely associated with lipid metabolism. We have demonstrated the presence of TM6SF2 in VSMCs within human atherosclerotic plaques. Subsequent functional studies were conducted to investigate its role in lipid uptake and accumulation in human vascular smooth muscle cells (HAVSMCs) using siRNA knockdown and overexpression techniques. Our results showed that TM6SF2 reduced lipid accumulation in oxLDL-stimulated VSMCs, likely through the regulation of lectin-like oxLD...
Source: Atherosclerosis - June 4, 2023 Category: Cardiology Authors: Ting-Ting Li Yu-Ting Cui Tao-Hua Li Qiong Xiang Yan-Yu Chen Xi-Long Zheng Juan Peng Zhi-Han Tang Source Type: research
Steep LDL Cholesterol Reductions With ANGPTL3 siRNA in HoFH Steep LDL Cholesterol Reductions With ANGPTL3 siRNA in HoFH
A single injection every 3 months of a novel drug that targets the lipid metabolism enzyme ANGPTL3 resulted in substantial reductions in LDL cholesterol in patients with HoFH in the phase 2 GATEWAY trial.Medscape Medical News
Source: Medscape Cardiology Headlines - June 1, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Puerarin-Tanshinone IIA Suppresses atherosclerosis inflammatory plaque via targeting succinate/HIF-1 α/IL-1β axis
CONCLUSION: This study confirmed that Pue-Tan blocked the succinate axis by targeting HIF-1α to prevent the formation of atherosclerotic inflammatory plaques and delay the pathological process of AS. Network Pharmacology, Bioinformatics of Molecular Docking, and Molecular Biology Validation can be used as a effective way to discover and verify the pharmacological mechanism of TCM.PMID:37257708 | DOI:10.1016/j.jep.2023.116675
Source: Atherosclerosis - May 31, 2023 Category: Cardiology Authors: Jingwen Xu Zhenhua Tian Zhe Li Xiaoshi Du Yansong Cui Jiangrong Wang Mei Gao Yinglong Hou Source Type: research
GADD34 activates p53 and may have utility as a marker of atherosclerosis
Front Med (Lausanne). 2023 May 9;10:1128921. doi: 10.3389/fmed.2023.1128921. eCollection 2023.ABSTRACTWe previously identified growth arrest and DNA-damage-inducible gene 34 (GADD34) as a marker of ischemic stroke. In the present study, serum levels of anti-GADD34 antibodies were found to be significantly higher in patients with acute ischemic stroke or chronic kidney disease compared to healthy donors. We then examined the biological function of GADD34 by transfection into U2OS human osteosarcoma and U87 human glioblastoma cells. Knockdown of GADD34 by siRNA resulted in enhanced cell proliferation, which was reversed by c...
Source: Atherosclerosis - May 25, 2023 Category: Cardiology Authors: Go Tomiyoshi Rika Nakamura Natsuko Shinmen Yoichi Yoshida Seiichiro Mine Toshio Machida Katsuro Iwase Yasuo Iwadate Takaki Hiwasa Hideyuki Kuroda Source Type: research
Endothelial PHACTR1 Promotes Endothelial Activation and Atherosclerosis by Repressing PPAR γ Activity Under Disturbed Flow in Mice
CONCLUSIONS: Our results identified endothelial PHACTR1 as a novel PPARγ corepressor to promote atherosclerosis in disturbed flow regions. Endothelial PHACTR1 is a potential therapeutic target for atherosclerosis treatment.PMID:37199156 | DOI:10.1161/ATVBAHA.122.318173
Source: Arteriosclerosis, Thrombosis and Vascular Biology - May 18, 2023 Category: Cardiology Authors: Dongyang Jiang Hao Liu Guofu Zhu Xiankai Li Linlin Fan Faxue Zhao Chong Xu Shumin Wang Yara Rose Jordan Rhen Ze Yu Yiheng Yin Yuling Gu Xiangbin Xu Edward A Fisher Junbo Ge Yawei Xu Jinjiang Pang Source Type: research
Lipoprotein(a) Lowering Medications - Another Step Forward in Atherosclerosis Management
J Cardiovasc Pharmacol. 2023 May 16. doi: 10.1097/FJC.0000000000001438. Online ahead of print.ABSTRACTASO and siRNA agents targeting Lp(a) appear to be promising treatment options for patients with elevated Lp(a) in addition to the classical therapies with statins or other cholesterol lowering drugs.PMID:37192439 | DOI:10.1097/FJC.0000000000001438
Source: Atherosclerosis - May 16, 2023 Category: Cardiology Authors: Boris B Boyanovsky Source Type: research
